Chronic Lymphocytic Leukemia and Myelofibrosis
Background. Chronic lymphocytic lymphoma (CLL) can be associated with several malignancies, but rarely with myelofibrosis. Only isolated case reports in the literature described the association between CLL and primary myelofibrosis (PMF) in the same patient. Objectives. We describe a case of CLL cha...
Saved in:
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2018-01-01
|
| Series: | Case Reports in Hematology |
| Online Access: | http://dx.doi.org/10.1155/2018/7426739 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832564255151357952 |
|---|---|
| author | Fares Darawshy Arieh Ben-Yehuda Karine Atlan Deborah Rund |
| author_facet | Fares Darawshy Arieh Ben-Yehuda Karine Atlan Deborah Rund |
| author_sort | Fares Darawshy |
| collection | DOAJ |
| description | Background. Chronic lymphocytic lymphoma (CLL) can be associated with several malignancies, but rarely with myelofibrosis. Only isolated case reports in the literature described the association between CLL and primary myelofibrosis (PMF) in the same patient. Objectives. We describe a case of CLL characterized by the development of PMF and a review of literature. Methods. We describe an 86-year-old female diagnosed as having CLL and followed by the development of splenomegaly and progressively rising LDH levels 27 months later. A bone marrow biopsy was consistent with the diagnosis of PMF, with positive JAK-2 V617F mutation. We also review the clinical and molecular characteristics of patients with CLL and PMF. Results. Patients with CLL and PMF are usually older. A lead diagnosis of CLL harbored by PMF is the most common clinical course, although concomitant diseases may occur in 31.7% of patients. JAK-2 V617F mutation can be found in 48.7% of patients. Conclusion. This case reported here constitutes an unusual situation of CLL characterized by the development of PMF. Etiologic and pathogenic associations—the role of t (1; 6) and JAK-2 V617F mutation—are discussed. |
| format | Article |
| id | doaj-art-3e09fa3fe5ac421ab99df9d88bb9fc77 |
| institution | Kabale University |
| issn | 2090-6560 2090-6579 |
| language | English |
| publishDate | 2018-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Case Reports in Hematology |
| spelling | doaj-art-3e09fa3fe5ac421ab99df9d88bb9fc772025-02-03T01:11:27ZengWileyCase Reports in Hematology2090-65602090-65792018-01-01201810.1155/2018/74267397426739Chronic Lymphocytic Leukemia and MyelofibrosisFares Darawshy0Arieh Ben-Yehuda1Karine Atlan2Deborah Rund3Internal Medicine Division, Internal Medicine C Department, Hebrew University-Hadassah Medical Organization, Jerusalem, IsraelInternal Medicine Division, Internal Medicine C Department, Hebrew University-Hadassah Medical Organization, Jerusalem, IsraelThe Pathology Institute, Hebrew University-Hadassah Medical Organization, Jerusalem, IsraelHematology Department, Hebrew University-Hadassah Medical Organization, Jerusalem, IsraelBackground. Chronic lymphocytic lymphoma (CLL) can be associated with several malignancies, but rarely with myelofibrosis. Only isolated case reports in the literature described the association between CLL and primary myelofibrosis (PMF) in the same patient. Objectives. We describe a case of CLL characterized by the development of PMF and a review of literature. Methods. We describe an 86-year-old female diagnosed as having CLL and followed by the development of splenomegaly and progressively rising LDH levels 27 months later. A bone marrow biopsy was consistent with the diagnosis of PMF, with positive JAK-2 V617F mutation. We also review the clinical and molecular characteristics of patients with CLL and PMF. Results. Patients with CLL and PMF are usually older. A lead diagnosis of CLL harbored by PMF is the most common clinical course, although concomitant diseases may occur in 31.7% of patients. JAK-2 V617F mutation can be found in 48.7% of patients. Conclusion. This case reported here constitutes an unusual situation of CLL characterized by the development of PMF. Etiologic and pathogenic associations—the role of t (1; 6) and JAK-2 V617F mutation—are discussed.http://dx.doi.org/10.1155/2018/7426739 |
| spellingShingle | Fares Darawshy Arieh Ben-Yehuda Karine Atlan Deborah Rund Chronic Lymphocytic Leukemia and Myelofibrosis Case Reports in Hematology |
| title | Chronic Lymphocytic Leukemia and Myelofibrosis |
| title_full | Chronic Lymphocytic Leukemia and Myelofibrosis |
| title_fullStr | Chronic Lymphocytic Leukemia and Myelofibrosis |
| title_full_unstemmed | Chronic Lymphocytic Leukemia and Myelofibrosis |
| title_short | Chronic Lymphocytic Leukemia and Myelofibrosis |
| title_sort | chronic lymphocytic leukemia and myelofibrosis |
| url | http://dx.doi.org/10.1155/2018/7426739 |
| work_keys_str_mv | AT faresdarawshy chroniclymphocyticleukemiaandmyelofibrosis AT ariehbenyehuda chroniclymphocyticleukemiaandmyelofibrosis AT karineatlan chroniclymphocyticleukemiaandmyelofibrosis AT deborahrund chroniclymphocyticleukemiaandmyelofibrosis |